Shandong LaiBo Biotechnology Co., Ltd., founded in 2005 with the registered capital of 87 million yuan, is a professional high-tech enterprise integrating R&D, production and distribution of the in vitro diagnostic products. Laibo has successfully developed more than 30 products. Eight products have successfully been granted certificate by CFDA. The “Diagnostic Kit for Core Antigen of Hepatitis C Virus” and the “Combined Diagnostic Kit for Core Antigen and Antibody of Hepatitis C Virus” are the first in China.

　　As the first company through the ISO13485 quality system certification in Ji'nan, Laibo has established standard quality management system of medical devices production and professional sales and service network throughout the country. More than 600 medical institutions are using Laibo products. So far, Laibo has been awarded such title as “the training base for Ji'nan medical device supervisors”, “Ji’nan Engineering Technology Research Center of the in vitro diagnostic reagent”, “Ji'nan Enterprise Technology Center”. In 2017 Laibo was approved by the National Postdoctoral Management Committee to establish the “National Postdoctoral research workstation”. That same year, Laibo was regarded as the “Gazelle Enterprise of National High-Tech Zones” by the Ministry of Science and Technology.

　　Laibo has undertaken 20 research projects and obtained 3 Trademark Registration Certificate by 2017. Laibo has been granted 12 National Invention Patent and has been awarded the Ministry of Education Technological Invention Award first prize, the Shandong Province Technological Invention Award second prize, the Ji’nan City Technological Invention Award first prize and the Ji’nan City Patent Award second prize.

　　With these achievements in scientific and technological innovation and the best service of all its competitors, Laibo has gradually become the leading enterprise in the in vitro diagnosis (IVD) field in China.